STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancreatic cancer: An open label, phase I/IIa trialResearch in context

Autor: Toshio Fujisawa, Takayoshi Tsuchiya, Motohiko Kato, Masafumi Mizuide, Kazuki Takakura, Makoto Nishimura, Hiromu Kutsumi, Yoko Matsuda, Tomio Arai, Shomei Ryozawa, Takao Itoi, Hiroyuki Isayama, Hideyuki Saya, Naohisa Yahagi

Publikováno v: EClinicalMedicine, Vol 55, Iss , Pp 101731- (2023)

Summary: Background: The impact of stroma-targeting therapy on tumor immune suppression is largely unexplored. An RNA oligonucleotide, STNM01, has been shown to repress carbohydrate sulfotransferase 15 (CHST15) responsible for tumor proteoglycan synt

Externí odkaz: https://doaj.org/article/4601cb53f7b14cf0b7ab8e6cab0a0da5

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancreatic cancer: An open label, phase I/IIa trial.

Autor: Fujisawa T; Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan., Tsuchiya T; Department of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan., Kato M; Division of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan., Mizuide M; Department of Gastroenterology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Takakura K; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo, Japan., Nishimura M; Department of Gastroenterology, Hepatology and Nutrition, Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Kutsumi H; Center for Clinical Research and Advanced Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan., Matsuda Y; Oncology Pathology, Department of Pathology and Host-Defense, Kagawa University, Takamastu, Kagawa, Japan., Arai T; Department of Pathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan., Ryozawa S; Department of Gastroenterology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Itoi T; Department of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan., Isayama H; Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan., Saya H; Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan., Yahagi N; Division of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Publikováno v: EClinicalMedicine [EClinicalMedicine] 2022 Nov 17; Vol. 55, pp. 101731. Date of Electronic Publication: 2022 Nov 17 (Print Publication: 2023).